Table 3.
Differentiated Thyroid Cancer and Thyroid Peroxidase Antibody Status
| Non-DTC n (%) | DTC n (%) | Total n (%) | Relative risk (95% CI) | |
|---|---|---|---|---|
| Non-HT | 1513 (70.3) | 638 (29.7) | 2151 (100) | — |
| Euth-HT | 32 (53.3) | 28 (46.7) | 60 (100) | 1.02 (1.00–1.03)a |
| TPO-High | ||||
| Euth-HT TPO-Low/Neg |
53 (46.1) | 62 (53.9) | 115 (100) | 1.08 (1.05–1.12)b |
| Hypo-HT | ||||
| LT4-Low TPO-High |
14 (53.8) | 12 (46.2) | 26 (100) | 1.01 (1.00–1.02) |
| LT4-Low TPO-Low/Neg |
1 (6.3) | 15 (93.7) | 16 (100) | 1.01 (1.00–1.02)b |
| LT4-Mid TPO-High |
15 (75.0) | 5 (25.0) | 20 (100) | 1.00 (0.99–1.01) |
| LT4-Mid TPO-Low/Neg |
7 (43.8) | 9 (56.2) | 16 (100) | 1.00 (1.00–1.01) |
| LT4-High TPO-High |
18 (85.7) | 3 (14.3) | 21 (100) | 1.00 (0.99–1.00) |
| LT4-High TPO-Low/Neg |
7 (46.7) | 8 (53.3) | 15 (100) | 1.00 (1.00–1.01) |
Relative risk is calculated compared to the Non-HT group by Fisher's exact test.
a
Fisher's exact test p<0.05.
b
Fisher's exact test p<0.001.
TPO, thyroid peroxidase antibodies; TPO-High, TPO antibodies titer>1:1000; TPO-Low/Neg, TPO antibodies titer<1:1000 or undetectable (negative); Non-HT, subjects without Hashimoto's thyroiditis; Euth-HT, euthyroid patients with Hashimoto's thyroiditis; Hypo-HT, hypothyroid patients with Hashimoto's thyroiditis; LT4, hypothyroid patients on levothyroxine replacement; Low/Mid/High, tertiles of levothyroxine replacement dose; DTC, differentiated thyroid cancer (see text for details); CI, confidence interval.